Albert Einstein College of Medicine

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1955-01-01

Employees: 1.9K

Market Cap: -

Website: http://einstein.yu.edu

Clinical Trials

Immunotoxin Therapy and Cytarabine in Treating Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Phase 1

Terminated

Conditions: Adult B Acute Lymphoblastic Leukemia
Recurrent Adult Acute Lymphoblastic Leukemia

Interventions: Drug: Cytarabine
Biological: Deglycosylated Ricin A Chain-Conjugated Anti-CD19/Anti-CD22 Immunotoxins
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study

First Posted Date: 2011-08-03

Last Posted Date: 2019-09-06

Lead Sponsor: Albert Einstein College of Medicine

Target Recruit Count: 18

Registration Number: NCT01408160

Locations: 🇺🇸
Albert Einstein College of Medicine, Bronx, New York, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Varenicline Smoking Cessation Treatment for Methadone Maintenance Patients

Not Applicable

Completed

Conditions: Tobacco Use Disorder
Medication Adherence

Interventions: Drug: Varenicline

First Posted Date: 2011-06-23

Last Posted Date: 2021-03-11

Lead Sponsor: Albert Einstein College of Medicine

Target Recruit Count: 100

Registration Number: NCT01378858

Locations: 🇺🇸
Albert Einstein College of Medicine, Bronx, New York, United States

Pilot Study of Resveratrol in Older Adults With Impaired Glucose Tolerance

Not Applicable

Completed

Conditions: Impaired Glucose Tolerance

Interventions: Dietary Supplement: resveratrol
Drug: Placebo

First Posted Date: 2011-06-20

Last Posted Date: 2022-10-26

Lead Sponsor: Albert Einstein College of Medicine

Target Recruit Count: 38

Registration Number: NCT01375959

Locations: 🇺🇸
Albert Einstein College of Medicine of Yeshiva University, Bronx, New York, United States

Project FIRST - Financial Incentives to Reduce Substance Use and Improve Treatment

Not Applicable

Completed

Conditions: HIV
Opiate Dependence

Interventions: Behavioral: Performance Feedback intervention
Behavioral: Abstinence-reinforcing contingency management intervention

First Posted Date: 2011-06-20

Last Posted Date: 2020-12-03

Lead Sponsor: Albert Einstein College of Medicine

Target Recruit Count: 242

Registration Number: NCT01376570

Locations: 🇺🇸
Montefiore's Community Clinics (Montefiore Medical Group), Bronx, New York, United States
🇺🇸
Albert Einstein College of Medicine Division of Substance Abuse clinics, Bronx, New York, United States
🇺🇸
Montefiore Infectious Disease Clinic, Bronx, New York, United States

Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer

Not Applicable

Terminated

Conditions: Uterine Carcinosarcoma
Stage IB Uterine Sarcoma
Stage IC Uterine Sarcoma
Stage IIB Uterine Sarcoma
Stage IVA Uterine Sarcoma
Stage IVB Uterine Sarcoma
Stage IA Uterine Sarcoma
Stage IIA Uterine Sarcoma
Stage IIIC Uterine Sarcoma
Stage IIIA Uterine Sarcoma

Interventions: Drug: paclitaxel
Drug: carboplatin
Radiation: external beam radiation therapy
Radiation: brachytherapy
Radiation: intensity-modulated radiation therapy
Other: laboratory biomarker analysis

First Posted Date: 2011-06-07

Last Posted Date: 2023-08-21

Lead Sponsor: Albert Einstein College of Medicine

Target Recruit Count: 14

Registration Number: NCT01367301

Locations: 🇺🇸
Albert Einstein College of Medicine, Bronx, New York, United States

Effect of Vitamin D Repletion on Insulin Resistance and Systemic Inflammation

Phase 2

Completed

Conditions: Insulin Resistance

Interventions: Drug: Placebo
Drug: Vitamin D

First Posted Date: 2011-05-17

Last Posted Date: 2020-11-02

Lead Sponsor: Albert Einstein College of Medicine

Target Recruit Count: 19

Registration Number: NCT01354964

Locations: 🇺🇸
Albert Einstein College of Medicine, Bronx, New York, United States

Effect of Resveratrol on Age-related Insulin Resistance and Inflammation in Humans

Phase 2

Completed

Conditions: Type 2 Diabetes Mellitus
Insulin Resistance

Interventions: Drug: Resveratrol

First Posted Date: 2011-05-17

Last Posted Date: 2022-03-08

Lead Sponsor: Albert Einstein College of Medicine

Target Recruit Count: 20

Registration Number: NCT01354977

Locations: 🇺🇸
Albert Einstein College of Medicine, Bronx, New York, United States

New Onset Type 1 Diabetes: Role of Exenatide

Phase 4

Completed

Conditions: Type 1 Diabetes

Interventions: Drug: Rapid and long acting insulin
Drug: long acting insulin + rapid acting + 1.25 mcg Exenatide
Drug: Exenatide

First Posted Date: 2011-01-04

Last Posted Date: 2021-08-04

Lead Sponsor: Albert Einstein College of Medicine

Target Recruit Count: 13

Registration Number: NCT01269034

Locations: 🇺🇸
Albert Einstein CRC- West Campus, Bronx, New York, United States

Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia

Phase 4

Completed

Conditions: Type 1 Diabetes

Interventions: Drug: Insulin
Drug: Pramlintide
Drug: Exenatide

First Posted Date: 2011-01-04

Last Posted Date: 2018-04-12

Lead Sponsor: Albert Einstein College of Medicine

Target Recruit Count: 37

Registration Number: NCT01269047

Locations: 🇺🇸
Albert Einstein College of Medicine West Campus Clinical Research Center, Bronx, New York, United States

Closed Loop System With Pramlintide Versus Exenatide

Phase 1

Completed

Conditions: Type 1 Diabetes

First Posted Date: 2011-01-04

Last Posted Date: 2018-02-20

Lead Sponsor: Albert Einstein College of Medicine

Target Recruit Count: 13

Registration Number: NCT01269008

Locations: 🇺🇸
Albert Einstein College of Medicine CRC, Bronx, New York, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy